Connect with us

Heartland

Vireo Health Q3 Revenue Increases 11% Sequentially to $11.9 Million

Vireo Health Announces Third Quarter 2020 Financial Results Total revenue of $13.4 million increased 68 percent year-over-year Gross margin of 42.7% reflects improving manufacturing efficiencies in core markets Christian Gonzalez promoted to role of COO; Patrick Peters promoted to EVP of Retail Revenue growth catalysts and cost discipline position Company for future margin improvement MINNEAPOLIS, […]

Republished by Plato

Published

on

Vireo Health Announces Third Quarter 2020 Financial Results
  • Total revenue of $13.4 million increased 68 percent year-over-year
  • Gross margin of 42.7% reflects improving manufacturing efficiencies in core markets
  • Christian Gonzalez promoted to role of COO; Patrick Peters promoted to EVP of Retail
  • Revenue growth catalysts and cost discipline position Company for future margin improvement

MINNEAPOLIS, Nov. 25, 2020 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), the science-focused, multi-state cannabis company with active operations in exclusively medical-only markets and licenses in six states and the Commonwealth of Puerto Rico, today reported financial results for its third quarter ended September 30, 2020. All currency figures referenced in this press release reflect U.S. dollar amounts.

Our third-quarter results demonstrate the improving nature of our business and success of recent initiatives to improve operating and financial performance.

Chairman and Chief Executive Officer, Kyle Kingsley, M.D.

For the past several quarters we’ve been focused on positioning our vertically-integrated portfolio of assets to produce sustained and profitable growth, and we believe today’s results are an encouraging indicator that we’re nearing a critical inflection point in cash flow generation from operations.

Dr. Kingsley continued, “Thanks to the hard work of our teams improving costs and manufacturing efficiencies, Vireo is positioned to improve margins as we continue growing our Green Goods™ retail dispensary footprint and benefit from likely tailwinds of regulatory changes. Each of our current development projects remain on time and budget, and with seven new dispensaries expected to open before the end of Q1 2021 and the potential for a majority of our state-based markets to pass adult-use legislation within the next year, we believe Vireo is poised for strong improvements in revenue growth and profitability.”

Third Quarter 2020 Financial Highlights

The Company generated revenue in seven states during the third quarter: Arizona, Maryland, Minnesota, New Mexico, New York, Ohio, and Pennsylvania. Total revenue, including contributions from discontinued operations, increased 68 percent year-over-year to $13.4 million. Reported revenue, excluding discontinued operations, was $11.9 million or an increase of 67 percent as compared to Q3 2019.

Retail revenue was approximately $9.9 million in Q3 2020, an increase of 61 percent compared to $6.2 million in Q3 2019. The increase in retail revenue was principally due to greater patient enrollment and average revenue per patient in Minnesota and New Mexico, as well as contributions from retail dispensaries in Pennsylvania. Wholesale revenue of $2.0 million increased by $1.1 million as compared to $980,921 in Q3 2019, with the increase primarily driven by the growth of wholesale operations in Maryland.

Gross profit before biological asset adjustments was $5.1 million, or 43 percent of revenue, as compared to gross profit of $1.8 million or 25 percent of revenue in the same period last year. The improvement in gross profit compared to the prior year was the result of operational efficiency gains in several markets, improved operating leverage through higher sales volumes and production facility upgrades completed last year.

Total operating expenses in the third quarter were $6.9 million, an improvement of $1.3 million or 16 percent as compared to $8.2 million in the third quarter of 2019. The reduction in operating expenses was attributable to lower professional fees and selling, general and administrative expenses including start-up expenses related to buildout and pre-revenue operations in some markets. Excluding depreciation and share-based compensation, operating expenses in the third quarter of 2020 were $6.1 million, or 51 percent of sales, as compared to $7.5 million or 105 percent of sales in the third quarter of 2019.

Total other income was $10.5 million during Q3 2020, compared to an expense of $825,868 in Q3 2019. The significant variance in other income as compared to the prior year quarter was primarily attributable to a one-time gain on the divestiture of the Company’s former Pennsylvania manufacturing and processing operations (“PAMS”) of $16.4 million. This transaction closed on August 11, 2020.

EBITDA, as described in accompanying disclosures and footnotes, was $8.1 million during Q3 2020, compared to a loss of $15.9 million in Q3 2019. Adjusted EBITDA was a loss of $675,808 in Q3 2020, as compared to a loss of $5.2 million in Q3 2019. Please refer to the Supplemental Information and Reconciliation of Non-IFRS Financial Measures at the end of this press release for additional information.

Net income in Q3 2020 was $122,252, as compared to a net loss of $14.6 million in Q3 2019. The favorable improvement in net income was primarily driven by the one-time gain of $16.4 million on the divestiture of the Company’s former PAMS subsidiary.

Subsequent Events

On October 1, 2020, Vireo announced that it reached a definitive agreement with Ayr Strategies Inc., to sell all the assets and liabilities of its affiliate, Ohio Medical Solutions, Inc. (“OMS”), for total consideration of $4.85 million, including $1.2 million in cash. This transaction is expected to close early next year.

On November 5, 2020, the Company announced that it entered into a non-binding term sheet with Green Ivy Capital and its affiliates for a proposed senior secured, delayed draw term loan with an aggregate principal amount of up to $46,000,000. Vireo management expects definitive loan documents for the funding of the first tranche to be executed in December 2020.

On November 9, 2020, the Company announced that it secured a purchase option on an additional 96 acres of land adjacent to its existing facilities in Fulton County, NY for a total purchase price of approximately US $1.3 million. This option could enable the Company to significantly expand its cultivation and processing capacity in the state in the event of favorable regulatory changes.

On November 13, 2020, a subsidiary of Jushi Holdings, Inc. notified Vireo of its intent to exercise its purchase option on Vireo’s subsidiary, Pennsylvania Dispensary Solutions (“PDS”) for $5.0 million cash. Vireo believes the closing of this transaction will occur in December 2020.

On November 16, 2020, the Company announced that it had exercised its right to force the redemption of all subordinate voting share purchase warrants issued to participants in the Company’s private placement offering which closed on March 10, 2020. This forced redemption is expected to result in the issuance of 13,651,574 additional subordinate voting shares and cash proceeds of approximately $10.0 million.

On November 23, 2020, the Company filed a preliminary base shelf prospectus with the securities regulators in each province of Canada, except for the Province of Quebec. The preliminary base shelf prospectus has not yet become final for the purpose of the sale of securities. The intention of the base shelf prospectus is to allow the Company to more efficiently access capital when market opportunities permit. The Company wishes to correct that the base shelf prospectus is for an amount of up to C$200 million not C$260 million as disclosed in the Company’s news release dated November 23, 2020.

This news release does not constitute an offer to sell or the solicitation of an offer to buy in the United States and the securities referred to in this news release may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933 or pursuant to an applicable exemption from the registration requirements under the U.S. Securities Act of 1933 and applicable state securities laws. A copy of the preliminary base shelf prospectus can be found on SEDAR at www.sedar.com.

Leadership Update

Today the Company also announced the promotions of Christian Gonzalez to the role of Chief Operating Officer and Patrick Peters to the role of Executive Vice President of Retail.

As Chief Operating Officer, Mr. Gonzalez will lead the Company’s nationwide manufacturing, retail, and product development teams. Christian joined Vireo in 2018 as General Manager in Pennsylvania and since then has overseen major capacity expansion projects and helped optimized manufacturing efficiencies at Vireo’s cultivation and processing facilities in Minnesota, New York, Maryland, Arizona, and New Mexico. He is an engineer and entrepreneur with over 15 years of manufacturing experience in the medical device, pharmaceutical and aerospace/defense industries.

As Executive Vice President of Retail, Mr. Peters’ responsibilities include the complete oversight of Vireo’s retail, ecommerce, and wholesale sales channels. Mr. Peters joined Vireo in 2019 to lead the Company’s retail growth initiatives which focused on the expansion of Green Goods™ retail store openings and re-brandings nationwide. He has over 20 years of retail marketing experience as an executive leader at brands such as Calvin Klein, Kate Spade, and Juicy Couture.

Planned Transition from IFRS to U.S. GAAP Reporting

The Company is currently in the process of transitioning to becoming a U.S. domestic registrant, and plans to begin presenting its financial statements in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”), rather than International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. Beginning in 2021, the Company expects to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K with the U.S. Securities and Exchange Commission. The Company anticipates incurring one-time expenses and professional fees related to this transition of approximately $0.5 million during the fourth quarter.

Balance Sheet and Liquidity

As of September 30, 2020, the Company had 37,337,138 equity shares issued and outstanding, and 155,376,287 shares outstanding on an as-converted, fully-diluted basis.

As of September 30, 2020, total current assets were $81.3 million, including cash on hand of $16.3 million, which does not include approximately $16.0 million in expected cash proceeds resulting from the redemption of warrants and divestitures of PDS and OMS. Total current liabilities were $20.7 million, with zero debt currently due within 12 months.

Outlook Commentary

Dr. Kingsley concluded, “As we exit fiscal year 2020, we’re focused on successfully completing our capacity expansion projects in Arizona, Maryland, and New Mexico, as well as our planned dispensary openings in Maryland, Minnesota and New Mexico. However, cash inflows from the forced redemption of warrants and exercise of the PDS purchase option materialized sooner than we anticipated, and our improving liquidity position has enabled us to begin evaluating additional investment opportunities. We expect to provide the investment community with an update on development initiatives and their potential impacts to our long-term operating and financial outlook in the spring of next year.”

Conference Call and Webcast Information

Vireo Health management will host a conference call with research analysts on Wednesday, November 25, 2020 at 8:30 a.m. ET (7:30 a.m. CT) to discuss its financial results for its third quarter ended September 30, 2020. Interested parties may register to attend the conference call via the following link: http://www.directeventreg.com/registration/event/8084816. Upon registration, each participant will be provided with call details and a registrant ID for Vireo’s conference ID number 8084816.

A live audio webcast of this event will also be available in the Events & Presentations section of the Company’s Investor Relations website at https://investors.vireohealth.com/events-and-presentations/default.aspx and will be archived for one year.

About Vireo Health International, Inc.

Vireo Health International, Inc. (“Vireo” or the “Company”) is a physician-led cannabis company focused on bringing the best of technology, science, and engineering to the cannabis industry. Vireo manufactures proprietary, branded cannabis products in environmentally-friendly, state-of-the-art greenhouses and other facilities and distributes its products through its growing network of Green GoodsTM retail dispensaries and through hundreds of third-party dispensaries in seven states. Vireo’s team of more than 425 employees, led by scientists, engineers, and cultivation experts, is focused on efficiency and the creation of best-in-class products, while driving scientific innovation within the cannabis industry and developing meaningful intellectual property. Today, Vireo is licensed to grow and/or process cannabis in seven markets. The Company is operational in six of those markets – including the core markets of Arizona, Maryland, Minnesota, New Mexico, and New York. The Company holds 29 total retail dispensary licenses, of which 11 are currently open for business. For more information about Vireo, please visit www.vireohealth.com.

Additional Information

Additional information relating to the Company’s third quarter 2020 results is available on SEDAR at www.sedar.com. Vireo refers to certain non-IFRS financial measures such as adjusted net income, Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and adjusted EBITDA (defined as earnings before interest, taxes, depreciation, amortization, less certain non-cash equity compensation expense, one-time transaction fees, and other non-cash items. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-IFRS Financial Measures at the end of this news release for more detailed information regarding non-IFRS financial measures.

Supplemental Information

The financial information reported in this press release is based on audited financial statements for the fiscal year ended December 31, 2019 and unaudited condensed interim consolidated financial statements for the third quarter ended September 30, 2020. All financial information contained in this press release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this press release is inconsistent with the information contained in the Company’s audited financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company’s audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

Reconciliation of Non-IFRS Financial Measures

EBITDA, Adjusted EBITDA, and Adjusted Operating Expenses are non-IFRS measures and do not have standardized definitions under IFRS. The following information provides reconciliations of the supplemental non-IFRS financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS. The Company has provided the non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. These supplemental non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the IFRS financial measures presented.

Reconciliation of Net Loss to Adjusted EBITDA

Reconciliation of Total Operating Expenses to Adjusted Operating Expenses

Original Press Release

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.


Get Our Sunday Newsletter


Source: https://www.newcannabisventures.com/vireo-health-q3-revenue-increases-11-sequentially-to-11-9-million/

Heartland

A Cannabis Grower’s Advice On Choosing The Right Strain

Editors Note: This is a guest post. If you have just started your journey with cannabis, the choice of the right strain will be the most overwhelming part. You will be surprised to see the variety on display at most dispensaries and online stores, and deciding on the face value is more challenging than you […]

The post A Cannabis Grower’s Advice On Choosing The Right Strain appeared first on Green Market Report.

Republished by Plato

Published

on

Editors Note: This is a guest post.

If you have just started your journey with cannabis, the choice of the right strain will be the most overwhelming part. You will be surprised to see the variety on display at most dispensaries and online stores, and deciding on the face value is more challenging than you imagine. It is something you need to learn because your experience depends on this selection. While strains can be confusing in the beginning, you can master them eventually and learn to pick the ones that promise the most incredible results. However, some guidance can take you a long way initially. Here is a cannabis grower’s advice that can guide you about choosing the right strain. 

Know the basics

First and foremost, you need to understand the attributes that make a weed strain unique. The plant contains different cannabinoids, with THC and CBD being the most significant ones. High-THC strains make you high, while those having more CBD are not intoxicating. You need to consider the THC-CBD ratio to pick a product that suits your needs. Another aspect to know is the terpene content, which gives a strain its characteristic aroma and flavors. Terpenes also support the effects of cannabinoids. Once you know these basics, you can choose a strain option according to your expectations. 

Consider your objective

While the profile of a cannabis strain is vital when it comes to picking the best option, you also need to consider the objective for consuming it. Cannabis works for medicinal or recreational purposes. While some strains offer extensive medicinal benefits for specific conditions, others have a recreational appeal. Yet others deliver on both fronts. For example, wedding cake strain is great for relieving mental issues such as anxiety, stress, and depression. It also offers a sedative and relaxed feeling if you only want to use it for recreational purposes. Your medical marijuana doctor will recommend a specific strain depending on your condition. Alternatively, you can seek advice from a budtender too.

Check the potency

Cannabis growers also recommend checking the potency of the strain before you start using it for your objective. Potency refers to the concentration of cannabinoids, particularly THC, in a weed strain. The ones with a higher potency give a more intense experience as compared to those with a lower potency. While you check the potency, you also need to be aware of your tolerance levels so that you do not end up getting intoxicated with a product you cannot handle.

Apart from the composition and effects of specific strains, another factor determining the choice is your budget. They come at different price points, from budget-friendly to high-end, and you need to opt for one that does not burn a hole in the pocket. Still, it makes sense to spend a little more on a strain that gets you a step closer to your expectations and delivers the benefits you look for. Finally, patience is the key when it comes to picking a strain that works for you. It is often a hit and trial process, and you only get better with time.


Post Views:
1

Source: https://www.greenmarketreport.com/a-cannabis-growers-advice-on-choosing-the-right-strain/?utm_source=rss&utm_medium=rss&utm_campaign=a-cannabis-growers-advice-on-choosing-the-right-strain

Continue Reading

Heartland

Flower One Names New CEO, Restructures Debt

Flower One Holdings Inc.  (OTCQX: FLOOF) completed an initial debt restructuring, closed on $10 million of a non-brokered convertible debenture offering that could rise to $25 million, and made changes to its Board of Directors and executive management team. The company recently defaulted on payments such as $262,500 due on January 1, 2021 in connection with […]

The post Flower One Names New CEO, Restructures Debt appeared first on Green Market Report.

Republished by Plato

Published

on

Flower One Holdings Inc.  (OTCQX: FLOOF) completed an initial debt restructuring, closed on $10 million of a non-brokered convertible debenture offering that could rise to $25 million, and made changes to its Board of Directors and executive management team. The company recently defaulted on payments such as $262,500 due on January 1, 2021 in connection with a loan from RB Loan Portfolio I, LLC  and lease payments in the amount of $526,677 due on January 5, 2021 in connection with the company’s lease of the greenhouse facility located at 3950 North Bruce Street in North Las Vegas.

Flower One had also not paid the January lease payment of $248,268 in connection with the lease of its cultivation and production facility at 343 Neeham Road in North Las Vegas, and interest payments due on two other loans (totaling $152,306 and $27,575), all of which were due January 1, 2021.

“Coupled with the Board and Management changes, the combination of the cash infusion, debt conversions, and debt and lease restructurings better positions the company’s Balance Sheet and debt service obligation,” said Interim CFO Richard Groberg. “With these steps, as well as recent cost rationalizations, Flower One has more flexibility to further its evolving cultivation, production, and sales strategies to serve the expanding Nevada market for cannabis consumption.”

New CEO

Kellen O’Keefe has been appointed from his previous position of Chief Strategy Officer to Flower One’s President and Interim Chief Executive Officer. Ken Villazor stepped down as Flower One’s Chief Executive Officer, President, and Chairman of the Board, positions he has held since January 1, 2018. Salpy Boyajian has been appointed as Executive Vice President, from her previous position of COO of Nevada Operations, and also has been appointed as Chairman of the Board.

“Today marks a transformational moment in Flower One’s history as we welcome prominent, industry-leaders to our Board of Directors as well as further strengthening our management team,” said O’Keefe. “We have taken the first steps towards properly capitalizing the business, restructuring our debt, and better positioning the Company for long-term success. We are excited about the future for cannabis in Nevada and are committed to our promise to deliver exceptional quality cannabis at accessible prices.”

Debt Restructuring

Flower One reached a modification agreement with its secured lender, RB Loan Portfolio II with respect to its existing $30 million term debt and with RB Loan Portfolio 1, LP, for an existing $16.9 million equipment financing. The company extended the maturity date from June 27, 2021, to December 21, 2021, and modified the interest rate to 14%, with 12% paid monthly and 2% paid at maturity, and the addition of an “Exit Fee” of $1 million payable upon payment in full of the Term Loan on the Maturity Date. Certain conditions were placed on the loan modification and the company listed them as follows:

  • the requirement that the Company pay certain previously defaulted obligations
  • that the Company complete of at least the Initial New Equity and the Subsequent New Equity by March 5, 2021
  • a Loan Modification Fee equal to 3% per annum on the outstanding principal of the Term Loan from May 19, 2020 until the “Effective Date” of the Term Loan Modification (January 25, 2021)
  • Flower One common shares in an amount equal to US$1,200,000 (with such common shares is subject to a six month lock-up agreement)
  • the grant of one-half warrant for each share granted, such warrants being exercisable for three years at a price of C$0.31, and reimbursement of Lender expenses

The company also entered into a Lease Modification Agreement with regard to the Master Lease Agreement dated February 1, 2019, for equipment lease financing of certain equipment at the Bruce St. Facility, pursuant to which the Lessor has agreed to forbear existing events of default and make certain modifications to Master Lease. The company was able to reduce the monthly payments. In connection with the Loan Modification Agreement, the company has issued US$1,200,000 worth of equity units.

Flower One closed on $10 million of a non-brokered Convertible Debenture Offering of up to $25 million “Debenture Units”. The company said expects to close the second tranche of the Offering at or about the end of February 2021. The net proceeds are intended to be used for working capital, previous debt obligations, and general corporate purposes. In connection with the initial closing under the offering, the company issued a total of 12,824 Debenture Units at a price of C$1,000 per Debenture Unit.

New Board Members

New additions to the Board include Mitchell Kahn, Eliza Gairard, and Kellen O’Keefe, effective January 26, 2021. Mr. Kahn, Mrs. Gairard, and Mr. O’Keefe will join the Board in addition to current Directors, Salpy Boyajian and Nitin Kaushal. Nitin Kaushal, who was recently appointed to the board, will serve as the Chair of the Company’s Audit, Risk and Finance Committee. Effective January 26, 2021, Amit Varma, David Wesley, and Ken Villazor have stepped down from the Board.


Post Views:
10

Source: https://www.greenmarketreport.com/flower-one-names-new-ceo-restructures-debt/?utm_source=rss&utm_medium=rss&utm_campaign=flower-one-names-new-ceo-restructures-debt

Continue Reading

Heartland

CBD Oil time to work

Republished by Plato

Published

on

So I’ve just consumed a 500mg £35 5% full spectrum CBD oil tincture in 3 days (I’ve been taking full droppers instead of ‘drops’ as recommended by accident) and I haven’t even had the benefits from that that I was looking for. I emailed the place I bought it from who are a really nice company that I’ve seen recommended on here quite a few times, and they said it’s better to take the drops in lower doses as they work slowly and better over a long period of time, is this correct? The dose in this case would be 5 mg twice a day. Also if I bought the 10% from their store and did a lower dosage like recommended would my tolerance be a bit ruined from taking such a high dose for the past few days?

I’m taking it for my anxiety and depression which I have struggled to find the right help for (tried therapy, anti depressants for years but nothings worked) and I was really hoping that CBD was going to work for me like I’ve seen it do for others. I appreciate any help!

Source: https://www.reddit.com/r/CBD/comments/l64e6r/cbd_oil_time_to_work/

Continue Reading
News2 days ago

Cansortium Inc. Appoints CEO Robert Beasley to Board of Directors

Heartland4 days ago

Looking for something similar to FEALS but less pricey.

Heartland1 day ago

is it possible for accidental thc product in my cbd cigarettes?

News5 days ago

Florida Lawmakers Pushing For Cannabis Law Changes And Reform

Heartland5 days ago

My new ‘Up in Smoke’ 40th Anniversary Rolling Tray! 🌱🎱😎 Love it! High Quality and Much Larger than Anticipated!

Heartland4 days ago

Anyone had issues ordering from the US to the uk

Heartland1 day ago

Can cbd help prevent hearing loss due to noise?

Heartland1 day ago

A good oil based sweetener?

Heartland1 day ago

Plant Power: Everyday Plants That Activate the Endocannabinoid System

Heartland4 days ago

Newbie questions regarding cbd & anxiety

Heartland4 days ago

1 dropper CBD VS 2 droppers CBD = dramatic contrast in effect

Heartland5 days ago

How CBD changed a young boy’s life

Heartland5 days ago

Quitting Nicotine

Heartland4 days ago

Anyone heard of or have tried this brand? Location near Dallas Texas

Heartland4 days ago

CBD oil causing issues with heart

Heartland5 days ago

Horizons ETFs to Launch World’s First Psychedelics-Focused ETF

Uncategorized5 days ago

USDA Final Rule on Hemp

Heartland19 hours ago

Build up of yellowy gold stuff inside vape tank. Is this the CBD content getting stuck? Can I extract it and dissolve it back into the E liquid?

Heartland5 days ago

Even Bernie is a fan of The Green Claw

Heartland4 days ago

What Is Kief And How To Use It | Honest Marijuana

Heartland4 days ago

CBG is so amazing for me! I guess it’s different for everyone but it has way more health benefits than CBD! I’ve been ordering by the case from centurioncbg, this is the best pain relief lotion I’ve ever had. Anyone try them yet? Or any CBG?

Heartland3 days ago

Can someone tell me what type of CBD liquid I’m supposed to put in a vape pen refillable cartridge?

Heartland5 days ago

Is this fine?

Heartland5 days ago

Mendo x Royal Kush

Heartland5 days ago

Mydecine Innovations Group Included in First-Ever Psychedelics ETF

Heartland3 days ago

pre-made tincture are more expensive?

Uncategorized2 days ago

Auxly Cannabis – The Clear Cut Way To Play Canadian Cannabis 2.0

Heartland1 day ago

The new Senate is the most cannabis-friendly in history. Tell your Senators to make this issue a priority!

Heartland3 days ago

What’s wrong with my CBD?

Heartland2 days ago

Transition from THC to CBD

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America